A phase I/II study of EYS606 for the treatment of non-infectious uveitis (NIU)
Phase of Trial: Phase I/II
Latest Information Update: 09 May 2017
At a glance
- Drugs EYS 606 (Primary)
- Indications Uveitis
- Focus Adverse reactions; First in man
- 09 May 2017 Professor Antoine Brezin is the principal investigator of the trial, according to an Eyevensys media release,
- 09 May 2017 According to an Eyevensys media release, the first patient has been successfully treated in this trial and initial trial results are expected in the first half of 2018.
- 09 May 2017 Status changed from planning to recruiting, according to an Eyevensys media release.